{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:56:38Z","timestamp":1787313398660,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bcp.2022.114914","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T18:30:24Z","timestamp":1642271424000},"page":"114914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition"],"prefix":"10.1016","volume":"197","author":[{"given":"Aya","family":"Hasan Alshammari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Masuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriho","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Wakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"issue":"9","key":"10.1016\/j.bcp.2022.114914_b0010","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73\u20134506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2022.114914_b0015","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/bjc.2012.153","article-title":"Regorafenib (BAY 73\u20134506) in advanced colorectal cancer: A phase I study","volume":"106","author":"Strumberg","year":"2012","journal-title":"Br. J. Cancer."},{"issue":"24","key":"10.1016\/j.bcp.2022.114914_b0020","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1158\/1078-0432.CCR-19-0470","article-title":"Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory\/Relapsed Leukemia or Solid Tumor Malignancies","volume":"25","author":"Inaba","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2022.114914_b0025","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy - classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"11","key":"10.1016\/j.bcp.2022.114914_b0030","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0035","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","article-title":"Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis","volume":"31","author":"Belum","year":"2013","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.bcp.2022.114914_b0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1529-8019.2011.01435.x","article-title":"Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib","volume":"24","author":"McLellan","year":"2011","journal-title":"Dermatol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2022.114914_b0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12079-016-0330-1","article-title":"Cellular mechanisms of skin repair in humans and other mammals","volume":"10","author":"Ritti\u00e9","year":"2016","journal-title":"J. Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.jidsymp.5650016","article-title":"Molecular mechanisms of VEGF-A action during tissue repair","volume":"11","author":"Eming","year":"2006","journal-title":"J. Investig. Dermatology. Symp. Proc."},{"key":"10.1016\/j.bcp.2022.114914_b0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jemt.10249","article-title":"Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix","volume":"60","author":"Li","year":"2003","journal-title":"Microsc. Res. Tech."},{"issue":"10","key":"10.1016\/j.bcp.2022.114914_b0060","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/wound.2013.0517","article-title":"Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair","volume":"3","author":"Johnson","year":"2014","journal-title":"Adv. Wound Care."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1158\/0008-5472.CAN-15-0694","article-title":"Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death","volume":"76","author":"Zimmerman","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2022.114914_b0070","doi-asserted-by":"crossref","first-page":"e102110","DOI":"10.1371\/journal.pone.0102110","article-title":"Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)","volume":"9","author":"Yamamoto","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2022.114914_b0075","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2022.114914_b0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2019.04.021","article-title":"Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients","volume":"83","author":"Ding","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"19","key":"10.1016\/j.bcp.2022.114914_b0085","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer."},{"issue":"11","key":"10.1016\/j.bcp.2022.114914_b0095","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/jid.2014.218","article-title":"Fas\/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction","volume":"134","author":"Yeh","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.bcp.2022.114914_b0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bcp.2022.114914_b0105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2022.114914_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13059-019-1879-9","article-title":"Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host","volume":"20","author":"Seishima","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.bcp.2022.114914_b0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11095-019-2695-3","article-title":"Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein","volume":"36","author":"Hashimoto","year":"2019","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.114914_b0125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nprot.2008.50","article-title":"Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice","volume":"3","author":"Lichti","year":"2008","journal-title":"Nat. Protoc."},{"issue":"67","key":"10.1016\/j.bcp.2022.114914_b0130","doi-asserted-by":"crossref","first-page":"111110","DOI":"10.18632\/oncotarget.22624","article-title":"Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-019-01593-w","article-title":"Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities","volume":"25","author":"Taguchi","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0140","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-010-1372-3","article-title":"A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer","volume":"67","author":"Tolcher","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.114914_b0145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.788","article-title":"Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients","volume":"57","author":"Nijenhuis","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: Focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2022.114914_b0160","first-page":"S78","article-title":"Pharmacokinetic-Guided Dosing of New Oral Cancer Agents","volume":"57","author":"Lucas","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2022.114914_b0165","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2022.114914_b0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2017.07.012","article-title":"Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma","volume":"472","author":"Rousset","year":"2017","journal-title":"Clin. Chim. Acta."},{"issue":"3","key":"10.1016\/j.bcp.2022.114914_b0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12185-017-2238-9","article-title":"Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study","volume":"106","author":"Tojo","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"14","key":"10.1016\/j.bcp.2022.114914_b0180","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.3390\/cancers13143425","article-title":"High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction","volume":"13","author":"Takahashi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2022.114914_b0185","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2022.114914_b0190","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1007\/s10637-011-9789-z","article-title":"Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors","volume":"30","author":"Takahashi","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"11","key":"10.1016\/j.bcp.2022.114914_b0195","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.734","article-title":"Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food","volume":"56","author":"Lamba","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2022.114914_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5361569","article-title":"Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature","volume":"2016","author":"Gen\u00e7ler","year":"2016","journal-title":"Dermatol. Res. Pract."},{"key":"10.1016\/j.bcp.2022.114914_b0205","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12032-012-0349-y","article-title":"Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis","volume":"30","author":"Yoshida","year":"2013","journal-title":"Med. Oncol."},{"issue":"10126","key":"10.1016\/j.bcp.2022.114914_b0210","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bcp.2022.114914_b0215","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdv.12172","article-title":"Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience","volume":"27","author":"Brazzelli","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.bcp.2022.114914_b0220","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2022.114914_b0225","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.21037\/jtd.2017.06.08","article-title":"The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0417-z","article-title":"COMFORT-I investigators, Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2022.114914_b0235","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin. Lung Cancer."},{"issue":"3","key":"10.1016\/j.bcp.2022.114914_b0240","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"43","key":"10.1016\/j.bcp.2022.114914_b0245","doi-asserted-by":"crossref","first-page":"75372","DOI":"10.18632\/oncotarget.18536","article-title":"Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bcp.2022.114914_b0250","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","article-title":"A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer","volume":"27","author":"Lacouture","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bcp.2022.114914_b0255","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2022.114914_b0260","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2022.114914_b0265","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0270","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10456-019-09679-9","article-title":"Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse","volume":"22","author":"Mukwaya","year":"2019","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.bcp.2022.114914_b0275","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2022.114914_b0280","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-020-0309-6","article-title":"s-HBEGF\/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide","volume":"30","author":"Luo","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.114914_b0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2022.114914_b0290","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.clinthera.2007.07.022","article-title":"Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors","volume":"29","author":"Adams","year":"2007","journal-title":"Clin. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222000089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222000089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:33:32Z","timestamp":1757770412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"alternative-id":["S0006295222000089"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.114914","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.114914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114914"}}